Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Covington
US Army
Farmers Insurance
US Department of Justice

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,987,262

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,987,262 protect, and when does it expire?

Patent 8,987,262 protects HEMANGEOL and is included in one NDA.

This patent has forty-six patent family members in thirty countries.

Summary for Patent: 8,987,262
Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Benoit (Bordeaux, FR)
Assignee: Universite de Bordeaux (Bordeaux, FR) Centre Hospitalier Universitaire de Bordeaux (Talence, FR)
Application Number:13/678,802
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,987,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD TO TREAT INFANTILE HEMANGIOMA ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,987,262

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07291273Oct 19, 2007

International Family Members for US Patent 8,987,262

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 068927 ➤ Sign Up
Austria 512661 ➤ Sign Up
Australia 2008313405 ➤ Sign Up
Brazil PI0816536 ➤ Sign Up
Canada 2701953 ➤ Sign Up
China 102006864 ➤ Sign Up
China 103169971 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
Fuji
Fish and Richardson
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.